Scientific Program

3rd International Conference on
PARKINSON’S DISEASE & MOVEMENT DISORDERS

September 25-26, 2017    Chicago, USA

UK: Conference Series llc LTD
47 Churchfield Road, London, W3 6AY
Toll Free: +1-800-216-6499
# Keynote Forum

### Introduction

**Title:** Management of psychosis in Parkinson’s disease  
**Syrus Scanland,** Dementia Connection® LLC, USA

### Panel Discussion

**Title:** The impact of wearing off on quality of life in patients with Parkinson’s disease  
**Srinivas Avathvadi Venkatesan,** DR.M.G.R. Medical University, India  
**Title:** Novel pharmaceutical interventions to relieve L-DOPA induced dyskinesia in Parkinson's disease  
**Jayakumar Rajadas,** Stanford University, USA

### Sessions:

**Epidemiology of Parkinson Disease | Neurocognitive Disorders**  
**Session Chair:** Srinivas Avathvadi Venkatesan, DR.M.G.R. Medical University, India

### Session Introduction

**Title:** Relationship between the stride length and cadence in patients with Parkinson’s disease  
**Míra Ambrus,** University of A Coruna, Spain

### Lunch Break

**Title:** Impact of vinpocetine on the therapeutic effectiveness of L-DOPA using rat model of Parkinson’s disease  
**Azza A Ali,** Al-Azhar University, Egypt

### Special Session

**Title:** Motor sensory stimulation (Modulation) in Parkinsonism  
**Srinivas Avathvadi Venkatesan,** DR.M.G.R. Medical University, India

### Session Introduction

**Title:** Somatosensory abnormalities in Parkinson’s disease and evidence from functional neuroimaging  
**Aimee J Nelson,** McMaster University, Canada

### Panel Discussion

**Title:** Discussing with your patients the importance of claiming pos-si-tive, uncovering your purpose and staying engaged  
**Martin M Baumann,** University of Louisville, USA  
**Title:** Novel insights and therapeutics for Parkinson’s disease  
**Harish C Pant,** National Institutes of Health, USA  
**Title:** Impairment of synaptic activity through reduced CaMKII activity in Parkinson’s disease model mice  
**Kohji Fukunaga,** Tohoku University, Japan
Hall - Vienna

Keynote Forum

Introduction

Title: Novel neuroimaging technique to study Parkinson's disease
Rajendra D Badgaiyan, University of Richmond, USA

Title: Complete communication of the potential medical and non-medical effects of Parkinson's on newly diagnosed patients by neurologists and movement disorder specialists
John M Baumann, University of Louisville, USA

Panel Discussion

Networking & Refreshment Break

Title: Nothobranchius furzeri: A new model organism of alpha-synucleinopathy
Tyrone Genade, Northwestern College, USA

Sessions:

Managing life with Parkinson's Disease | Novel Insights and Therapeutics for Parkinson's Disease
Session Chair: Jayakumar Rajadas, Stanford University, USA

Session Introduction

Title: Reprogramming and programming of human hindbrain cells
Jianfeng Lu, Tongji University, China

Title: Improvement quality of life of people with Parkinson's disease by physical and psychosocial approach: Experience of Kaunas UAS/Kauno Kolegija project
Viktorija Piscalkiene, Kaunas University of Applied Sciences, Lithuania

Title: Synthetic steps towards reversible chalcogen-based sensing of essential neurodegenerative disease factors
Tesla Yudhistira, Korea Advanced Institute of Science and Technology, Korea

Lunch Break

Title: If I knew then, what I know now … the definitive guide for those who do not have a chronic illness
John M Baumann, University of Louisville, USA

Panel Discussion

Special Session

Title: Novel disease-modifying drugs inhibiting alpha-synuclein aggregation in Parkinson's disease model mice
Kohji Fukunaga, Tohoku University, Japan

Poster Presentations

P1 Title: Olfactory hallucination in a super smeller
Weller A, Carribbean Medical University School of Medicine, USA

P2 Title: Modulatory effects of bisphenol A, caffeine, epigallocatechin-3-gallate and their combinations against parkinsonism in rats
Azza A Ali, Al-Azhar University, Egypt

P3 Title: Comparative study on the potential role of cocoa, epigallocatechin-3-gallate, coenzyme Q10 and their combination against manganese-induced parkinsonian like syndrome in rats
Azza A Ali, Al-Azhar University, Egypt

P4 Title: 9-tert-butyl-apomorphine (DTBA) as an effective soluble compound with antioxidant activity for treatment of experimental Parkinsonism
G Shilau, Belarussian State University, Belarus

Panel Discussion

Networking & Refreshment Break

Award Ceremony

Thanks Giving & Closing Ceremony
Day 1  December 05, 2016

09:00-09:30  Registrations

Conference Hall

09:30-09:55  Opening Ceremony

Keynote Forum

09:55-10:00  Introduction
Title: A small peptide derived from a neuronal cell cycle like kinase activator, P35, is a possible therapeutic candidate to reduce the phenotypes of neurodegenerative disorders
Harish C Pant, NINDS-NIH, USA

10:00-10:40
Title: Degeneration of the Thalamostriatal System: A Potential Source of Early Cognitive Impairments in Parkinson's Disease
Yoland Smith, Emory University, USA

Refreshments @10:40-11:00

11:00-11:40
Title: Preventing Parkinson's
Bennett Weinstock, Weinstock Physical Therapy, PC, USA

11:40-12:20
Title: Articulatory Kinematics and speech dysfunction in patients with Parkinson's disease
Srinivas Avathvadi Venkatesan, Hershe Medical College, USA

Session Chair: Yoland Smith, Emory University, USA

Workshop

11:40-12:20
Title: St. Jude Medical
Jeff Kramer, St. Jude Medical, USA

Sessions: Parkinsons: Pathophysiology and Neuropharmacology | Neuromuscular and Neurocognitive Disorders

Session Chair: Yoland Smith, Emory University, USA

12:20-12:50
Title: Clinical Trials using MRI Guided Focused Ultrasound (ExAblate Transcranial System) for the management of Medically-Refractory Dyskinesias Symptoms of advanced Idiopathic Parkinson's Disease and in patients with Benign Essential Tremors
Charlene Aldrich, University of Maryland School of Medicine, USA

Title: Parkinson's Disease is not a Disease
Rudy Capildeo, Nuffield Hospital, UK

12:50-13:20
Title: What makes a parkinson patient fall
Bhanu Kesavamurthy, Madras Medical College, India

Lunch Break 13:20-14:10

14:10-14:40
Title: Clinical Conundrum of Neuroleptic Malignant Syndrome - A New Look and a New AVS-CUV Criterion
Srinivas Avathvadi Venkatesan, Hershe Medical College, USA

14:40-15:10
Title: Nesfatin-1 protects dopaminergic neurons against MPTP neurotoxicity through C-Raf/ERK1/2 dependent anti-apo
Hong Jiang, Qingdao University, China

Title: Exercise prescriptions for Parkinson diseases
Bennett Weinstock, Weinstock Physical Therapy, USA

15:10-15:40
Title: Impact of Sirtine 3 in cognitove deficits in Parkinson’s disease
Jie Wu, Barrow Neurological Institute, USA

Refreshments 15:40-16:00

16:00-16:40
Title: Parkinson's: The First Consultation – My Approach
Rudy Capildeo, Nuffield Hospital, UK

Panel Discussion

Day 2  December 06, 2016

Conference Hall

Keynote Forum

10:00-10:40
Title: Parkinson’s: The First Consultation – My Approach
Rudy Capildeo, Nuffield Hospital, UK

Refreshments 10:50-11:10

11:10-11:50
Title: Clinical Conundrum of Neuroleptic Malignant Syndrome - A New Look and a New AVS-CUV Criterion
Srinivas Avathvadi Venkatesan, Hershe Medical College, USA

Sessions: Diagnosis of Parkinsons | Risk factors in Parkinsons | Mananging Life in Parkinsons Disease

Session Chair: Rudy Capildeo, Nuffield Hospital, UK

11:50-12:20
Title: Nesfatin-1 protects dopaminergic neurons against MPTP neurotoxicity through C-Raf/ERK1/2 dependent anti-apo
Hong Jiang, Qingdao University, China

Title: Exercise prescriptions for Parkinson diseases
Bennett Weinstock, Weinstock Physical Therapy, USA
Title: Disrupted-in-schizophrenia1 (DISC1) L100P mutation alters synaptic transmission and plasticity in the hippocampus and causes recognition memory deficits  
Yu Zhou, Qingdao University, China


14:10-14:40 Title: Dystonia profile in a tertiary care hospital from southern India  
Prabaharan Chellamuthu, Madras Medical College, India

Title: Inhibition of high mobility group box 1 (HMGB1) as a neuroprotective treatment in the MPTP mouse model of Parkinson's disease.  
Matteo Santoro, University of Aberdeen, UK

Title: Effect of Delayed Post-Treatment With Adult-Sourced Adipose-Derived Mesenchymal Stem Cells on Motor Function and Striatal Medium-Spiny Projection Neurons After Neonatal Rat Hypoxia-Ischemia  
Benjamin E. Aghoghovwia, University of Otago, New Zealand

15:10-16:10 Panel Discussion

Day 3 December 07, 2016
Conference Hall

Srinivas Avathvadi Venkatesan, Hershe Medical College, USA

Session Introduction

10:00-10:30 Title: Dopamine D1 and D2 receptor subtypes functional regulation in unilateral rotenone lesioned Parkinson's rat model: Effect of serotonin, dopamine and norepinephrine  
Jes Paul, American University of St. Vincent, St. Vincent and the Grenadines

Refreshments 10:30-10:50

Workshop

Usman Shabbir, Comsats Institutes of Information Technology, Pakistan

Panel Discussion

Poster Presentations @ 11:50-13:30

PD1 Title: Activation of NLRP3-inflammasome in the MPTP mouse model of Parkinson's disease might be triggered by HMGB1-MAC-1 axis  
Matteo Santoro, University of Aberdeen, UK

PD2 Title: Grape skin powder mediates mitochondria function by autophagy activation and exhibits potential protective benefit in a Drosophila Parkinson's Disease Model  
Alan Wu, Stanford University, USA

PD3 Title: Disorder of action preparation in schizophrenia  
Denisas Dankinas, Vilnius University, Lithuania

PD4 Title: Role of Therapeutic Touch in the management of responsive behavior in patients with dementia  
Helen Senderovich, University of Toronto, Canada

PD5 Title: Next Generation Sequencing data analysis evaluation in patients with Parkinsonism from genetically isolated population  
Radek Vodicka, Palacky University, Czech Republic

PD6 Title: Differences in vulnerability of neurons and astrocytes to heme oxygenase-1 modulation: Implications for mitochondrial ferritin  
Junxia Xie, Qingdao University, China

PD7 Title: Bioinorganic Implications and Strategies in Parkinson's Disease  
Heather R. Lucas, Virginia Commonwealth University, USA

PD8 Title: Acceleration of de novo early bone defect healing following application of s-nitroso glutathione in vivo  
Xin Wang, Queensland University of Technology, Australia

PD9 Title: Dystonia profile in a tertiary care hospital from southern India  
Prabaharan Chellamuthu, Madras Medical College, India

Lunch Break: 13:30-14:15

14:15-14:45 Title: Holistics support services for individual's with movement disorders  
Steven Szydlowski, University of Scranton, USA

Title: Integration of Palliative Care in the management of Parkinson's disease  
Helen Senderovich, University of Toronto, Canada

Panel Discussion 15:15-15:45

Networking and B2B Meeting@16:05-17:00

Award & Closing Ceremony
Scientific Program

International Conference on
Parkinson’s Disease & Movement Disorders

August 11-13, 2015   Frankfurt, Germany
### Keynote Forum

**09:55-10:00 Introduction**

**10:00-10:40 Kjell Fuxe**  
Karolinska Institutet, Sweden

**10:40-11:20 Michael Ugrumov**  
Institute of Developmental Biology RAS, Russia

**Session on: Associate Disorders like Neurocognitive and Degenerative Disorder**

**Session Chair: Ekaterina Rogaeva, University of Toronto, Canada**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 11:40-12:10| Movement disorder and neurodegeneration in a rat model with myosin 5a mutation  
George Stoica, Texas A&M University, USA |
| 12:10-12:40| Mutation analysis of CHCHD10 in neurodegenerative diseases, including Parkinson's disease  
Ekaterina Rogaeva, University of Toronto, Canada |
| 12:40-13:10| Analysis of volatile organic compounds in rats with dopaminergic lesion: Possible application for early detection of Parkinson's disease  
Soliman Khatib, MIGAL–Galilee Research Institute, Israel |

**Lunch Break 13:10-14:00 @ Restaurant**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 14:00-14:30| The concentration of oxidized DJ-1 protein (oxDJ-1) in red blood cells is useful for the diagnosis method of Parkinson's disease  
Kazumasa Saigoh, Kinki University, Japan |

### Session Discussion

**14:30-16:00 Workshop on: On the role of A1-D1 heteroreceptor complexes in the direct pathway in models of Parkinson's disease by Dasiel O Borroto Escuela, Karolinska Institutet, Sweden**

**Session on: Basic Science and Epidemiology**

**Session Chair: Michael Ugrumov, Institute of Developmental Biology RAS, Russia**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 16:30-17:00| Prevalence of Parkinson's disease in Egypt: A review of community-based survey  
Eman Khedr, Assiut University, Egypt |
| 17:00-17:30| The effect of systemic inflammation induced by a high sucrose diet, on inflammation in the rat substantia nigra  
Ashton Rogers, University of the West Indies, West Indies |

**Coffee Break 11:20-11:40 @ Foyer**

**Coffee Break 16:00-16:30 @ Foyer**
Raume / Room - 4
Day 2 August 12, 2015

Keynote Forum

10:00-10:40  Robert W Ledeen
New Jersey Medical School, USA

10:40-11:20  George Stoica
Texas A&M University, USA

Coffee Break 11:20-11:40 @ Foyer

Session on: Novel Insights and Therapeutics for Parkinson’s Disease
Session Chair: Kjell Fuxe, Karolinska Institutet, Sweden

Session Introduction

11:40-12:10  Neuroplasticity in the Nigrostriatal system of MPTP-treated mice at presymptomatic and early symptomatic stages of parkinsonism
Michael Ugrumov, RAS Center for Brain Research, Russia

12:10-12:40  Use of human embryonic stem cells in the treatment of Parkinson's disease
Geeta Sharoff, Nutech Mediworld, India

Lunch Break 12:40-13:30 @ Restaurant

13:30-14:00  Evaluation of a rhythmic exercise program for patients with Parkinson’s disease
Audun Myskja, Norwegian Parkinson Org, Norway

14:00-14:30  Dyskinesia associated with old and new therapies in Parkinson’s disease
Sanjay Jaiswal, Jaiswal Hospital and Neuro Institute, India

14:30-15:30  Workshop on: The impact of DA heteroreceptor complexes and their receptor-receptor interactions in Parkinson’s disease and its treatment by Kjell Fuxe, Karolinska Institutet, Sweden

Session Discussion

Coffee Break 15:30-16:00 @ Foyer

Young Researcher Forum

16:00-16:30  The effects of increased therapy time on cognition and mood in frail patients with a stroke who rehabilitate on rehabilitation units of nursing homes in the Netherlands
Marleen Huijben, University of Amsterdam, Netherlands

16:30-17:00  Hyperkinetic movement disorders, differential diagnosis and treatment
Arunasalam Balamanogaran, Gomel State Medical University, Belarus

Poster Presentations @ 17:00-17:45

PDMD-001  Curcumin’s neuroprotective efficacy in drosophila model of idiopathic Parkinson’s disease is phase specific: Implications of its therapeutic effectiveness
Limamanen Phom, Nagaland University, India

PDMD-002  Protective effects of rosmarinic acid against iron-induced neurotoxicity in SK-N-SH cells
Huamin Xu, Qingdao University, China

PDMD-003  Mice expressing the A53T mutant form of human alpha-synuclein exhibit unexpected improvements of spatial learning and memory abilities
Ze Gang Ma, Qingdao University, China

PDMD-004  Bidirectional modulation by HCN channels on globus pallidus neurons
Lei Chen, Qingdao University, China

PDMD-005  GPER agonist G1 attenuates LPS-induced inflammatory responses in murine BV-2 microglial cells
Wen-fang Chen, Qingdao University, China

PDMD-006  Sulforaphane ameliorates 3-nitropropionic acid-induced striatal toxicity by activating the Keap1-Nrf2-ARE pathway and inhibiting the MAPKs and NF-kB pathways
Ik-Hyun Cho, Kyung Hee University, Republic of Korea

PDMD-007  Protective effects and mechanisms of rosmarinic acid against rotenone-induced Parkinson’s disease models
Jun-xia Xie, Qingdao University, China

PDMD-008  NR2B Antagonist ifenprodil improves abnormal forelimb movement induced by D1R agonist SKF38393 in hemiparkinsonian rats
Toshiya Habata, Kitasato University, Japan
<table>
<thead>
<tr>
<th>Session Introduction</th>
<th>Session Chair: Kjell Fuxe, Karolinska Institutet, Sweden</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00-10:30</td>
<td>Thioredoxin-1 suppresses MPP+/MPTP neurotoxicity through enhancing autophagy</td>
</tr>
<tr>
<td>Bai Jie, Kunming University of Science and Technology, China</td>
<td></td>
</tr>
<tr>
<td>10:30-11:00</td>
<td>On the role of A1-D1 heteroreceptor complexes in the direct pathway in models of Parkinson's disease</td>
</tr>
<tr>
<td>Dasiel O Borroto Escuela, Karolinska Institutet, Sweden</td>
<td></td>
</tr>
<tr>
<td>Coffee Break 11:00-11:30 @ Foyer</td>
<td></td>
</tr>
<tr>
<td>11:30-12:00</td>
<td>The impact of DA heteroreceptor complexes and their receptor-receptor interactions in Parkinson's disease and its treatment</td>
</tr>
<tr>
<td>Kjell Fuxe, Karolinska Institutet, Sweden</td>
<td></td>
</tr>
<tr>
<td>12:00-12:30</td>
<td>New gene therapy approaches for Parkinson's disease</td>
</tr>
<tr>
<td>Jose Lanciego, Center for Applied Medical Research (CIMA and CIBERNED), Spain</td>
<td></td>
</tr>
<tr>
<td>Lunch Break 12:30-13:30 @ Restaurant</td>
<td></td>
</tr>
</tbody>
</table>

**Raume / Room - 4**

**Day 3 August 13, 2015**

Session on: Novel Insights and Therapeutics for Parkinson's Disease

**Session Chair: Kjell Fuxe, Karolinska Institutet, Sweden**

<table>
<thead>
<tr>
<th>Session Introduction</th>
<th>Session Chair: Kjell Fuxe, Karolinska Institutet, Sweden</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00-10:30</td>
<td>Thioredoxin-1 suppresses MPP+/MPTP neurotoxicity through enhancing autophagy</td>
</tr>
<tr>
<td>Bai Jie, Kunming University of Science and Technology, China</td>
<td></td>
</tr>
<tr>
<td>10:30-11:00</td>
<td>On the role of A1-D1 heteroreceptor complexes in the direct pathway in models of Parkinson's disease</td>
</tr>
<tr>
<td>Dasiel O Borroto Escuela, Karolinska Institutet, Sweden</td>
<td></td>
</tr>
<tr>
<td>Coffee Break 11:00-11:30 @ Foyer</td>
<td></td>
</tr>
<tr>
<td>11:30-12:00</td>
<td>The impact of DA heteroreceptor complexes and their receptor-receptor interactions in Parkinson's disease and its treatment</td>
</tr>
<tr>
<td>Kjell Fuxe, Karolinska Institutet, Sweden</td>
<td></td>
</tr>
<tr>
<td>12:00-12:30</td>
<td>New gene therapy approaches for Parkinson's disease</td>
</tr>
<tr>
<td>Jose Lanciego, Center for Applied Medical Research (CIMA and CIBERNED), Spain</td>
<td></td>
</tr>
<tr>
<td>Lunch Break 12:30-13:30 @ Restaurant</td>
<td></td>
</tr>
</tbody>
</table>

**Bookmark your dates**

**2nd International Conference on Parkinson’s Disease & Movement Disorders**

December 08-10, 2016  Philadelphia, USA

Website: [http://parkinsons.conferenceseries.com](http://parkinsons.conferenceseries.com)